Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 61 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Treatment for Bipolar I Disorder Clear all
Completed Phase 4 Interventional

Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder

NCT00181779
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
aripiprazole (Abilify)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Oct 2, 2026, 7:54 PM EDT
Completed Not applicable Interventional

Mindfulness-Based Cognitive Behavior Therapy for Bipolar Disorder

NCT01126827
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Mindfulness-Based Cognitive Behavioral Therapy or Supportive Psychotherapy
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2011 · Synced Oct 2, 2026, 7:54 PM EDT
Withdrawn Phase 4 Interventional

Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old

NCT01932541
View directory record Official record
Conditions
Mania, Bipolar I, Bipolar II, Bipolar Spectrum Disorder, Bipolar Disorder
Interventions
Latuda (Lurasidone)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 2, 2026, 7:54 PM EDT
Completed Phase 2 Interventional Results available

12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression

NCT02363738
View directory record Official record
Conditions
Bipolar Depression
Interventions
Infliximab, Saline
Drug · Other
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 2, 2026, 7:54 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

NCT06929273
View directory record Official record
Conditions
Bipolar Disorder Type I With Mania
Interventions
KarXT, Lithium, Valproate, Lamotrigine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
61
States / cities
Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 2, 2026, 7:54 PM EDT
Completed Phase 3 Interventional Results available

Staccato Loxapine in Agitated Patients With Bipolar Disorder

NCT00721955
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Inhaled Placebo, Inhaled loxapine 5 mg, Inhaled loxapine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Escondido, California • Garden Grove, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 2, 2026, 7:54 PM EDT
Not listed Phase 4 Interventional

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

NCT03881449
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
Interventions
ABILIFY MYCITE
Combination Product
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 2, 2026, 7:54 PM EDT
Completed Not applicable Interventional

Emotion Regulation Group Therapy for Bipolar Disorder

NCT01207505
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Enhancing Emotion Regulation
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 2, 2026, 7:54 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

NCT05227209
View directory record Official record
Conditions
Depressive Episodes, Bipolar I Depression
Interventions
SEP-4199 CR
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Huntsville, Alabama • Anaheim, California • Imperial, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 2, 2026, 7:54 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder

NCT00114686
View directory record Official record
Conditions
Bipolar I Disorder, Alcohol Dependence
Interventions
Quetiapine fumarate, lithium, divalproex
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 60 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
38
States / cities
Cerritos, California • San Diego, California • New Haven, Connecticut + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 2, 2026, 7:54 PM EDT
Completed Phase 3 Interventional Results available

Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial

NCT00852592
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Episode
Interventions
7000lux broad-spectrum light, 50lux dim red light
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 2, 2026, 7:54 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder

NCT03257865
View directory record Official record
Conditions
Bipolar I Disorder, Manic Episode
Interventions
Brexpiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Little Rock, Arkansas • Bellflower, California • Cerritos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 2, 2026, 7:54 PM EDT
Completed Phase 3 Interventional

A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder

NCT00232414
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 2, 2026, 7:54 PM EDT
Recruiting No phase listed Observational

Children's Bipolar Network Treatment Trial I

NCT05427123
View directory record Official record
Conditions
Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder, Other Specified Bipolar and Related Disorder, Mood Instability, Child Mental Disorder, Adolescent - Emotional Problem
Interventions
Medication or psychosocial treatment
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
9 Years to 19 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 2, 2026, 7:54 PM EDT
Active, not recruiting Phase 2 Interventional

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

NCT07046494
View directory record Official record
Conditions
Bipolar 1 Disorder
Interventions
RAP-219, Placebo
Drug · Other
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Chino, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 2, 2026, 7:54 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

NCT06951698
View directory record Official record
Conditions
Bipolar-I Disorder With Mania or Mania With Mixed Features
Interventions
KarXT, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
23
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 2, 2026, 7:54 PM EDT
Terminated Phase 2 Interventional Results available

NeoSync TMS Treatment for Bipolar I Depression

NCT02839798
View directory record Official record
Conditions
Major Depressive Episode, Bipolar Depression, Bipolar Disorder, Mood Disorders
Interventions
NEST (NeoSync EEG Synchronized TMS)
Device
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 2, 2026, 7:54 PM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder

NCT02670538
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
42
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 2, 2026, 7:54 PM EDT
Completed Phase 4 Interventional

Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder

NCT00181870
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
carbamazepine ER (Equetro)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Oct 2, 2026, 7:54 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

NCT06951711
View directory record Official record
Conditions
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Interventions
KarXT, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 2, 2026, 7:54 PM EDT
Terminated Phase 4 Interventional Results available

Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder

NCT00592358
View directory record Official record
Conditions
Pediatric Bipolar Disorder
Interventions
paliperidone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 4, 2012 · Synced Oct 2, 2026, 7:54 PM EDT
Completed Phase 4 Interventional Results available

Sequential Multiple Assignment Treatment for Bipolar Disorder

NCT01588457
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder
Interventions
Lithium, Divalproex, Lamotrigine, Quetiapine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 2, 2026, 7:54 PM EDT
Completed Not applicable Interventional

LiveWell: A Mobile Intervention for Bipolar Disorder

NCT03088462
View directory record Official record
Conditions
Bipolar Disorder, Bipolar I Disorder
Interventions
Psychiatric management, Psychosocial treatment, LiveWell Program
Other · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 2, 2026, 7:54 PM EDT
Completed Phase 3 Interventional Results available

Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

NCT00868959
View directory record Official record
Conditions
Bipolar Depression
Interventions
lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
817 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
58
States / cities
Little Rock, Arkansas • Anaheim, California • Chino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 2, 2026, 7:54 PM EDT